To boost the immunogenicity of the tumor antigen, hepatitis B core protein virus-like particles (OVA-HBc VLPs) were fused with the tumor antigen peptide (OVA257–264: SIINFEKL) (Figure 6). Here, KRT88P is linked to neoplasm.